Eli Lilly Retained Earnings (Accumulated Deficit) 2010-2024 | LLY

Eli Lilly retained earnings (accumulated deficit) for the quarter ending December 31, 2024 were $13.545B, a 31.35% increase year-over-year.

  • Eli Lilly retained earnings (accumulated deficit) for 2024 were $13.545B, a 31.35% increase from 2023.
  • Eli Lilly retained earnings (accumulated deficit) for 2023 were $10.312B, a 2.69% increase from 2022.
  • Eli Lilly retained earnings (accumulated deficit) for 2022 were $10.043B, a 12.1% increase from 2021.

Eli Lilly Retained Earnings (Accumulated Deficit) 2010-2024 | LLY

  • Eli Lilly retained earnings (accumulated deficit) for 2024 were $13.545B, a 31.35% increase from 2023.
  • Eli Lilly retained earnings (accumulated deficit) for 2023 were $10.312B, a 2.69% increase from 2022.
  • Eli Lilly retained earnings (accumulated deficit) for 2022 were $10.043B, a 12.1% increase from 2021.
Related Stocks
Company NameMarket
Cap
Johnson & Johnson (JNJ)$380.1B
Novo Nordisk (NVO)$374.3B
AbbVie (ABBV)$348.4B
Roche Holding AG (RHHBY)$259.5B
Novartis AG (NVS)$218.5B
Merck (MRK)$216.5B
Pfizer (PFE)$146.7B
Sanofi (SNY)$136B
Bayer (BAYRY)$22B
Innoviva (INVA)$1.1B